Core Insights - The investment philosophy emphasizes finding undervalued assets in forgotten market segments, focusing on long-term value rather than short-term market fluctuations [1][2][3] Investment Strategy - The investment approach is characterized by a commitment to being fully invested since the fund's inception in June 2017, prioritizing the discovery of quality stocks with a safety margin [2][3] - The focus is on identifying undervalued individual stocks rather than timing the market, with a belief that the core of investment lies in continuous discovery of undervalued opportunities [2][3] Market Focus - Current investment interests include sectors that have been temporarily overlooked, such as leading companies in the liquor industry and the home furnishing supply chain [3] - The strategy involves a cautious approach to the AI industry, recognizing its potential but avoiding high-valuation stocks due to a lack of deep understanding and the current market valuations [4][5] Sector Analysis - The copper mining sector is highlighted as a promising investment due to its affordability and growth potential, driven by increasing demand from AI infrastructure, electric vehicles, and renewable energy [5] - The belief is that the copper market may face a significant supply gap in the next five to ten years, influenced by various technological and infrastructural demands [5] Long-term Perspective - The long-term outlook for the Chinese capital market is rooted in the entrepreneurial spirit of Chinese entrepreneurs, with expectations for the emergence of competitive and innovative companies [6][7] - The investment philosophy encourages a continuous learning mindset across various industries, focusing on fundamental analysis and recognizing personal limitations in investment capabilities [7]

Core Viewpoint - The investment strategy focuses on identifying undervalued assets in forgotten market segments, emphasizing a bottom-up approach to uncover hidden opportunities during market fluctuations [1][2]. Group 1: Investment Philosophy - The company maintains a fully invested position since its inception in June 2017, demonstrating a commitment to long-term value rather than short-term market timing [2]. - The core investment philosophy revolves around finding high-quality stocks with a safety margin, rather than attempting to predict overall market trends [2][3]. - The investment approach is characterized by a focus on valuation and market cycles, with a belief that low prices provide strong safety margins and potential for significant upside when cycles recover [2][4]. Group 2: Current Market Focus - The company is currently exploring opportunities in sectors such as leading liquor brands and the home furnishings industry, which have been temporarily overlooked by the market [3]. - Despite the AI industry's prominence, the company remains cautious, citing high valuations and a lack of deep understanding of the rapidly evolving sector [3][4]. - The company identifies copper mining stocks as attractive investments due to their reasonable valuations and significant growth potential driven by increasing demand from AI infrastructure and renewable energy [4]. Group 3: Long-term Outlook - The long-term market outlook is driven by the entrepreneurial spirit of Chinese businesses, with expectations for the emergence of competitive companies that create new demand [4][5]. - The investment strategy is likened to "turning stones," emphasizing continuous learning and analysis of industry fundamentals, competitive dynamics, and management effectiveness [4][5]. - The company acknowledges the inevitability of mistakes in the investment process, viewing them as part of a learning journey that contributes to long-term value accumulation [5].

Summary of Key Points from the Conference Call Industry Overview - The pharmaceutical industry faced revenue pressure in Q1 2025, with varied performance across segments. Biologics grew by 12% driven by overseas business, hospitals increased by 6.7%, and medical consumables rose by 1.8% [1][3][4]. Core Insights and Arguments - **CXO and IVD Focus**: Public fund holdings indicate that CXO (Contract Research Organization) and IVD (In Vitro Diagnostics) are key market focuses. Companies like WuXi AppTec and Kelun are benefiting from overseas business, with high capacity utilization [1][4]. - **CXO Characteristics**: The CXO sector in Q1 2025 showed strong overseas-driven growth, with improved domestic new orders but overall performance lagging behind international results. Leading companies exhibit strong stability, while smaller firms are relatively weaker [5][6]. - **IVD Sector Decline**: The IVD industry experienced negative growth in Q1 2025, with reagent consumption declining year-on-year. The chemiluminescence sector performed better due to import substitution, while companies like Mindray faced challenges from mature business impacts [1][9]. - **Policy Impact on IVD**: Domestic policies such as DRG 2.0 and medical service price adjustments significantly affected the IVD sector, leading to decreased testing prices and reduced profitability for channels, impacting overall testing volumes [10]. Additional Important Insights - **Medical Equipment Recovery**: The medical equipment sector showed signs of recovery, with a more than 60% year-on-year increase in procurement in Q1 2025, particularly in tertiary hospitals. Expectations for better performance in the second half of the year are optimistic [1][16]. - **Investment Opportunities**: Areas with potential for high growth include innovative drugs, CXO, biologics, and hospital services, driven by new product launches and increased international market demand [7][21]. - **Market Trends**: The medical device sector is expected to improve in the second half of 2025, with procurement demand recovering after a significant decline in 2024 [14][16]. - **International Market Influence**: Chinese medical device companies are seeing significant contributions from international markets, with notable growth rates in overseas business for companies like Mindray and United Imaging [17]. Fund Holdings and Market Sentiment - **Biopharmaceutical Fund Allocation**: In Q1 2025, biopharmaceuticals accounted for 9.2% of the top ten fund holdings, indicating a positive sentiment towards the sector despite a historical trend of under-allocation since 2021 [18][19]. - **Hospital Sector Holdings**: The hospital sector saw a drastic reduction in fund allocation from nearly 18% to just 1%, reflecting uncertainty about sustainable growth in the near term [20]. Conclusion - The pharmaceutical and medical sectors are experiencing a mixed landscape, with certain areas like CXO and innovative drugs showing promise for growth, while IVD faces challenges from policy changes and market dynamics. The overall sentiment remains cautiously optimistic, with potential investment opportunities in recovering sectors.